FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2741349657> ?p ?o ?g. }

• W2741349657 endingPage "5628" @default.
• W2741349657 startingPage "5628" @default.
• W2741349657 abstract "Abstract While immune checkpoint inhibitors are efficacious and lead to durable responses in patients with various cancers, only a minority of patients respond. An approach to increase the response rate of immune checkpoint inhibitors is to combine them with chemotherapy in order to enhance immunogenic cell death and “prime” the immune system. However, chemotherapy itself can cause damage to various cell types of the immune system, potentially diminishing the activity of the chemotherapy/checkpoint inhibitor combination. Therefore, a targeted approach to preserve immune system function during chemotherapy would allow optimal activity of the checkpoint inhibitor therapy. Trilaciclib (G1T28), a potent and selective IV CDK4/6 inhibitor, preserves hematopoietic stem cells and enhances immune system function during chemotherapy. We and others have previously shown T lymphocytes are extremely sensitive to CDK4/6 inhibition causing a transient arrest of proliferation and protection from damage by chemotherapy. Post treatment with trilaciclib and chemotherapy, T lymphocytes are released from the transient arrest in the presence of chemotherapy-induced immunogenic cell death allowing better priming of an anti-tumor immune response. To evaluate the effect of trilaciclib combination treatments, MC38 tumor bearing mice were treated with trilaciclib, oxaliplatin, or anti-PD-L1 alone or in combination, and tumor size was measured during and post treatment for 100 days. Our results demonstrate that the addition of trilaciclib to an oxaliplatin/anti-PD-L1 combination (TOP) treatment significantly improves anti-tumor activity. Specifically, twice as many mice treated with TOP for 15 days had a complete response (CRs) when compared to oxaliplatin/anti-PD-L1 (OP); 6/10 CRs vs 3/10 CRs, respectively. In addition, the CRs were durable and without any evidence of recurrence at 100 days. Furthermore, TOP treatment caused a 60% increase in overall survival (OS) compared to mice treated with OP; median OS for TOP was 98 days compared to 61 days (HR, 0.53) for the OP treatment group. Assessment of ex-vivo stimulation of cytokine release from harvested splenocytes to measure T-cell activation, and evaluation of immune infiltrates and T-cell receptor repertoire within the tumors are ongoing. Taken together, we demonstrate that the short-acting IV CDK4/6 inhibitor, trilaciclib, which has been shown to preserve immune function during chemotherapy, enhances the anti-tumor activity of chemotherapy/anti-PD-L1 combination therapy. Citation Format: Jessica A. Sorrentino, Anne Y. Lai, Jay C. Strum, Patrick J. Roberts. Trilaciclib (G1T28), a CDK4/6 inhibitor, enhances the efficacy of combination chemotherapy and immune checkpoint inhibitor treatment in preclinical models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5628. doi:10.1158/1538-7445.AM2017-5628" @default.
• W2741349657 created "2017-08-08" @default.
• W2741349657 creator A5043074491 @default.
• W2741349657 creator A5058971478 @default.
• W2741349657 creator A5065243123 @default.
• W2741349657 creator A5078598967 @default.
• W2741349657 date "2017-07-01" @default.
• W2741349657 modified "2023-10-16" @default.
• W2741349657 title "Abstract 5628: Trilaciclib (G1T28), a CDK4/6 inhibitor, enhances the efficacy of combination chemotherapy and immune checkpoint inhibitor treatment in preclinical models" @default.
• W2741349657 doi "https://doi.org/10.1158/1538-7445.am2017-5628" @default.
• W2741349657 hasPublicationYear "2017" @default.
• W2741349657 type Work @default.
• W2741349657 sameAs 2741349657 @default.
• W2741349657 citedByCount "6" @default.
• W2741349657 countsByYear W27413496572019 @default.
• W2741349657 countsByYear W27413496572020 @default.
• W2741349657 countsByYear W27413496572021 @default.
• W2741349657 countsByYear W27413496572022 @default.
• W2741349657 countsByYear W27413496572023 @default.
• W2741349657 crossrefType "journal-article" @default.
• W2741349657 hasAuthorship W2741349657A5043074491 @default.
• W2741349657 hasAuthorship W2741349657A5058971478 @default.
• W2741349657 hasAuthorship W2741349657A5065243123 @default.
• W2741349657 hasAuthorship W2741349657A5078598967 @default.
• W2741349657 hasConcept C100701293 @default.
• W2741349657 hasConcept C121608353 @default.
• W2741349657 hasConcept C126322002 @default.
• W2741349657 hasConcept C203014093 @default.
• W2741349657 hasConcept C2776694085 @default.
• W2741349657 hasConcept C2777701055 @default.
• W2741349657 hasConcept C2777877232 @default.
• W2741349657 hasConcept C2780851360 @default.
• W2741349657 hasConcept C2780962732 @default.
• W2741349657 hasConcept C502942594 @default.
• W2741349657 hasConcept C526805850 @default.
• W2741349657 hasConcept C59822182 @default.
• W2741349657 hasConcept C71924100 @default.
• W2741349657 hasConcept C81444415 @default.
• W2741349657 hasConcept C86803240 @default.
• W2741349657 hasConcept C8891405 @default.
• W2741349657 hasConcept C98274493 @default.
• W2741349657 hasConceptScore W2741349657C100701293 @default.
• W2741349657 hasConceptScore W2741349657C121608353 @default.
• W2741349657 hasConceptScore W2741349657C126322002 @default.
• W2741349657 hasConceptScore W2741349657C203014093 @default.
• W2741349657 hasConceptScore W2741349657C2776694085 @default.
• W2741349657 hasConceptScore W2741349657C2777701055 @default.
• W2741349657 hasConceptScore W2741349657C2777877232 @default.
• W2741349657 hasConceptScore W2741349657C2780851360 @default.
• W2741349657 hasConceptScore W2741349657C2780962732 @default.
• W2741349657 hasConceptScore W2741349657C502942594 @default.
• W2741349657 hasConceptScore W2741349657C526805850 @default.
• W2741349657 hasConceptScore W2741349657C59822182 @default.
• W2741349657 hasConceptScore W2741349657C71924100 @default.
• W2741349657 hasConceptScore W2741349657C81444415 @default.
• W2741349657 hasConceptScore W2741349657C86803240 @default.
• W2741349657 hasConceptScore W2741349657C8891405 @default.
• W2741349657 hasConceptScore W2741349657C98274493 @default.
• W2741349657 hasIssue "13_Supplement" @default.
• W2741349657 hasLocation W27413496571 @default.
• W2741349657 hasOpenAccess W2741349657 @default.
• W2741349657 hasPrimaryLocation W27413496571 @default.
• W2741349657 hasRelatedWork W1996150995 @default.
• W2741349657 hasRelatedWork W2398164441 @default.
• W2741349657 hasRelatedWork W2886039816 @default.
• W2741349657 hasRelatedWork W3006273887 @default.
• W2741349657 hasRelatedWork W3216801484 @default.
• W2741349657 hasRelatedWork W4206840735 @default.
• W2741349657 hasRelatedWork W4241449638 @default.
• W2741349657 hasRelatedWork W4281723870 @default.
• W2741349657 hasRelatedWork W4360983034 @default.
• W2741349657 hasRelatedWork W4379467849 @default.
• W2741349657 hasVolume "77" @default.
• W2741349657 isParatext "false" @default.
• W2741349657 isRetracted "false" @default.
• W2741349657 magId "2741349657" @default.
• W2741349657 workType "article" @default.